Shanghai RAAS Blood Products Co Ltd Class A002252
▼ NegativeCapitalrelevance
Net profit down 35.80% year-on-year in interim report

Shanghai RAAS released its 2026 interim report, with net profit attributable to the parent company of 661 million yuan, a decrease of 35.80% compared with the same period last year. The company's total operating revenue was 3.209 billion yuan, down 18.79% year-on-year; net cash inflow from operating activities was 405 million yuan, down 45.20% year-on-year. The latest asset-liability ratio was 13.46%, gross margin was 35.09%, ROE was 2.04%, and diluted earnings per share was 0.10 yuan.
Shanghai RAAS Blood Products Co Ltd Class ANet profit down 35.80% year-on-year in interim report